CEC Capital advises Zhongkexinyang on 100-million-yuan private financing roundPUBT·1 day ago, 07:09 PM
Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development LifecycleUnusual Whales·Jul 28 at 10:42 AM
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-RezLondon Stock Exchange·Jul 28 at 05:06 AMGSK-0.73%03692-0.49%
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderUnusual Whales·Jul 27 at 06:03 AMCAMP-0.58%
INNOSTAR (688710): Won the procurement project of Tongji University, with a bid amount of 1.82 million yuan同壁财经·May 26 at 04:29 AM688710+0.58%
The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declinesWallstreetcn·Mar 19 at 01:30 AM300016+2.63%688136+3.63%
Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to SemaglutideWallstreetcn·Feb 2 at 09:45 AM688710+0.58%159859+1.32%
What obesity drugmakers see next in the market: More pills, easier access and drug combinationsCNBC·Jan 23 at 06:00 AMBIB-3.70%FBT-3.01%
The CRO index's intraday increase expanded to 3%, Medicilon hit the limit up, JOINN, Bide, Sun-Novo, and INNOSTAR followed suitZhitong·Jul 8, 2025 at 10:04 PM603127+3.72%061270.00%
INNOSTAR: The holding subsidiary Shenzhen INNOSTAR will undergo business adjustmentsZhitong·Jun 24, 2025 at 05:50 AM688710+0.58%
INNOSTAR: Net profit of RMB 5.5185 million in the first quarter of 2025, a year-on-year decrease of 90.33%Zhitong·Apr 29, 2025 at 08:48 AM688710+0.58%
INNOSTAR: Clinical Immunohistochemistry Laboratory has passed CAP certificationZhitong·Mar 4, 2025 at 02:51 AM688710+0.58%
Shanghai Innostar Biotechnology Full Year 2024 Earnings: EPS: CN¥1.26 (vs CN¥1.84 in FY 2023)Simplywall·Mar 3, 2025 at 08:11 PM688710+0.58%
INNOSTAR's net profit for 2024 is 148 million yuan, a year-on-year decrease of 24%Zhitong·Feb 27, 2025 at 09:53 AM688710+0.58%
